The collaboration aims to integrate these algorithms into routine eye examinations, facilitating the diagnosis of CKD.

Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for the treatment of hypertension in subjects with CKD ...

In Radin’s eyes, the FLOW data make "semaglutide stand out uniquely amongst the options that are available for patients with type 2 diabetes and chronic kidney disease.” ...

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s Ozempic (semaglutide) to reduce certain risks associated with chronic kidney disease (CKD). The Danish drugmaker’s popular ...

In the latest in a string of biotech acquisitions, Amgen says it is buying KAI Pharmaceuticals for ... hyperparathyroidism in patients with chronic kidney disease. It's the only therapy listed ...

Manoj Saxena, Managing Director, Bayer Zydus Pharma said “Finerenone offers a new treatment approach for the vulnerable patients to slow down the progression of CKD and reduce the risk of kidney ...